Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LATISHA D HEINLEN

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1649430810
CMS profile
1235381
Location
OKLAHOMA CITY, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$95,227.27

270 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 6; records 51–100 of 270 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LATISHA D HEINLEN

NPI 1649430810 · CMS profile ID 1235381

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

OKLAHOMA CITY, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 270 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649430810?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LATISHA D HEINLEN, NPI 1649430810, CMS profile ID 1235381. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 270 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649430810?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). LATISHA D HEINLEN, NPI 1649430810, CMS profile ID 1235381. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 270 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649430810?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
LATISHA D HEINLEN, NPI 1649430810, CMS profile ID 1235381, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 270 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1649430810?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

270 matching records · $95,227.27 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 270 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 270.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Fresenius Kabi USA, LLC $14.3810/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060097037 CMS
ABBVIE INC. $10.2310/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997460189 CMS
Genentech USA, Inc. $13.4410/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040432822 CMS
Genentech USA, Inc. $2.4410/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040432829 CMS
GENZYME CORPORATION $140.2209/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050110335 CMS
GENZYME CORPORATION $17.3609/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050110311 CMS
Amgen Inc. $24.6809/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019997229 CMS
ABBVIE INC. $17.7809/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997460187 CMS
Janssen Biotech, Inc. $275.0009/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988495995 CMS
ABBVIE INC. $11.7009/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997460185 CMS
AstraZeneca Pharmaceuticals LP $12.7509/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016201011 CMS
Novartis Pharmaceuticals Corporation $24.8509/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991985925 CMS
ABBVIE INC. $1,200.0009/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997460181 CMS
ABBVIE INC. $1,200.0009/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997460183 CMS
Amgen Inc. $12.0809/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019997219 CMS
Amgen Inc. $14.8509/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019997221 CMS
Horizon Therapeutics plc $18.0009/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987018003 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.8709/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996569359 CMS
ABBVIE INC. $14.4609/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997460179 CMS
Organon LLC $18.4209/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046991773 CMS
Lilly USA, LLC $31.6708/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031903361 CMS
Janssen Biotech, Inc. $23.8608/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988496063 CMS
UCB, Inc. $24.2608/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021498361 CMS
GlaxoSmithKline, LLC. $15.6008/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002654161 CMS
ABBVIE INC. $11.3908/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997460177 CMS
Amgen Inc. $11.9308/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020621275 CMS
Novartis Pharmaceuticals Corporation $27.0608/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991985921 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.5108/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997091107 CMS
Sandoz Inc. $25.3708/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1028940497 CMS
ABBVIE INC. $20.4708/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997460175 CMS
AstraZeneca Pharmaceuticals LP $14.9808/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014814485 CMS
Mylan Institutional Inc. $18.4608/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039010513 CMS
Amgen Inc. $18.2008/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019997237 CMS
ABBVIE INC. $1,200.0008/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997460173 CMS
Amgen Inc. $21.8808/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019997227 CMS
AstraZeneca Pharmaceuticals LP $25.6108/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011293679 CMS
GENZYME CORPORATION $19.0208/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050110283 CMS
ABBVIE INC. $15.4508/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997460171 CMS
Janssen Biotech, Inc. $275.0008/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988495985 CMS
GENZYME CORPORATION $130.9608/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050110279 CMS
Janssen Biotech, Inc. $25.4407/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988496073 CMS
Organon LLC $26.6407/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046991761 CMS
Amgen Inc. $16.9907/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019997245 CMS
Lilly USA, LLC $13.4507/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031876707 CMS
ABBVIE INC. $9.2207/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997460169 CMS
UCB, Inc. $16.9807/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021514919 CMS
Genentech USA, Inc. $14.2007/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040432857 CMS
Amgen Inc. $17.9607/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019997217 CMS
Fresenius Kabi USA, LLC $16.3007/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060097041 CMS
Horizon Therapeutics plc $23.4107/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987017999 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $125,482.99 343
PY2020 $59,356.47 188
PY2021 $88,934.65 205
PY2022 $94,797.13 234
PY2023 $95,227.27 270
PY2024 $115,061.59 294
PY2025 $95,964.30 269

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $770.81 1
PY2025 Principal investigator $459,962.74 50
PY2024 Recipient $28,555.27 2
PY2024 Principal investigator $247,601.77 31
PY2023 Principal investigator $254,095.35 58
PY2022 Principal investigator $190,630.87 75
PY2021 Principal investigator $30,012.95 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $2,240.00 12/19/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175425642
Principal investigator 1 ABBVIE INC. $500.00 12/18/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202531166
Principal investigator 1 ABBVIE INC. $3,000.00 12/18/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202531180
Principal investigator 1 ABBVIE INC. $2,400.00 12/18/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202531190
Principal investigator 1 SANOFI US SERVICES INC. $31.00 12/15/2025 Non-covered Recipient Entity
Rao Research Llc
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226128991
Principal investigator 1 Novartis Pharmaceuticals Corporation $26.10 11/15/2025 Non-covered Recipient Entity
RHEUMATOLOGY ASSOCIATES OF OKLAHOMA
A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) No dispute reported 06/30/2026 1190308628
Principal investigator 1 ABBVIE INC. $3,983.85 11/05/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202522865
Principal investigator 1 ABBVIE INC. $3,137.00 10/09/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202515283
Principal investigator 1 Novartis Pharmaceuticals Corporation $292.77 10/08/2025 Non-covered Recipient Entity
RHEUMATOLOGY ASSOCIATES OF OKLAHOMA
A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease No dispute reported 06/30/2026 1190308480
Principal investigator 1 Novartis Pharmaceuticals Corporation $125.85 10/08/2025 Non-covered Recipient Entity
RHEUMATOLOGY ASSOCIATES OF OKLAHOMA
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190308624
Principal investigator 1 Janssen Research & Development, LLC $500.00 09/15/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175425607
Principal investigator 1 SANOFI US SERVICES INC. $565.84 09/15/2025 Non-covered Recipient Entity
Rao Research Llc
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226128886
Principal investigator 1 SANOFI US SERVICES INC. $225.00 09/15/2025 Non-covered Recipient Entity
Rao Research Llc
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226128890
Principal investigator 1 ABBVIE INC. $6,375.00 09/04/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202508866
Principal investigator 1 ABBVIE INC. $11,620.00 09/04/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202508868
Principal investigator 1 ABBVIE INC. $1,811.00 09/03/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202507393
Principal investigator 1 Amgen Inc. $291.65 08/26/2025 Non-covered Recipient Entity
RHEUMATOLOGY ASSO.OF OKLAHOMA
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity No dispute reported 06/30/2026 1246647321
Principal investigator 1 ABBVIE INC. $1,941.00 08/05/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202501232
Principal investigator 1 SANOFI US SERVICES INC. $325.00 07/14/2025 Non-covered Recipient Entity
Rao Research Llc
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226128836
Principal investigator 1 Janssen Research & Development, LLC $1,368.00 07/07/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175425636
Principal investigator 1 SANOFI US SERVICES INC. $4,257.50 07/02/2025 Non-covered Recipient Entity
Rao Research Llc
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226128839
Principal investigator 1 SANOFI US SERVICES INC. $3,000.00 06/16/2025 Non-covered Recipient Entity
Rao Research Llc
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226128768
Principal investigator 1 SANOFI US SERVICES INC. $910.00 06/09/2025 Non-covered Recipient Entity
Rao Research Llc
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226128755
Principal investigator 1 ABBVIE INC. $6,741.00 06/03/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202489727
Principal investigator 1 Novartis Pharmaceuticals Corporation $880.00 06/03/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) No dispute reported 06/30/2026 1190311853
Principal investigator 1 Janssen Research & Development, LLC $500.00 06/02/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175425627
Principal investigator 1 Janssen Research & Development, LLC $500.00 06/02/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175425633
Principal investigator 1 Janssen Research & Development, LLC $1,200.00 05/23/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175425617
Principal investigator 1 ABBVIE INC. $65.00 05/22/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202485851
Principal investigator 1 SANOFI US SERVICES INC. $4,200.00 05/19/2025 Non-covered Recipient Entity
Rao Research Llc
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226128784
Principal investigator 1 ABBVIE INC. $2,500.00 05/15/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202485059
Principal investigator 1 ABBVIE INC. $1,470.00 05/15/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202485061
Principal investigator 1 ABBVIE INC. $6,858.00 05/06/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202481761
Recipient Eli Lilly and Company $770.81 04/23/2025 Covered Recipient Physician EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187871067
Principal investigator 1 Janssen Research & Development, LLC $26,559.00 04/17/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175425612
Principal investigator 1 SANOFI US SERVICES INC. $6,857.50 04/14/2025 Non-covered Recipient Entity
Rao Research Llc
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226128720
Principal investigator 1 ABBVIE INC. $1,941.00 04/03/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202473554
Principal investigator 1 Eli Lilly and Company $294.00 04/03/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187888722
Principal investigator 1 Janssen Research & Development, LLC $2,520.00 03/31/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175425622
Principal investigator 1 SANOFI US SERVICES INC. $7,507.50 03/17/2025 Non-covered Recipient Entity
Rao Research Llc
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226128690
Principal investigator 1 SANOFI US SERVICES INC. $6,305.00 02/24/2025 Non-covered Recipient Entity
Rao Research Llc
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226128621
Principal investigator 1 Eli Lilly and Company $54,117.79 02/11/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187887922
Principal investigator 1 Novartis Pharmaceuticals Corporation $19,900.95 02/10/2025 Non-covered Recipient Entity
RHEUMATOLOGY ASSOCIATES OF OKLAHOMA
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190308626
Principal investigator 1 ABBVIE INC. $1,941.00 02/05/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202445726
Principal investigator 1 Novartis Pharmaceuticals Corporation $156,247.24 01/28/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease No dispute reported 06/30/2026 1190311849
Principal investigator 1 Novartis Pharmaceuticals Corporation $26,954.00 01/28/2025 Non-covered Recipient Entity
RAO RESEARCH LLC
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190311851
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,549.59 01/21/2025 Non-covered Recipient Entity
Rheumatology Associates Of Oklahoma
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment No dispute reported 06/30/2026 1235994227
Principal investigator 1 SANOFI US SERVICES INC. $4,420.00 01/21/2025 Non-covered Recipient Entity
Rao Research Llc
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226128635
Principal investigator 1 SANOFI US SERVICES INC. $155.00 01/21/2025 Non-covered Recipient Entity
Rao Research Llc
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226128702
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,260.50 01/15/2025 Non-covered Recipient Entity
RHEUMATOLOGY ASSOCIATES OF OKLAHOMA
A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) No dispute reported 06/30/2026 1190308630
Principal investigator 1 Novartis Pharmaceuticals Corporation $63,592.11 01/09/2025 Non-covered Recipient Entity
RHEUMATOLOGY ASSOCIATES OF OKLAHOMA
A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease No dispute reported 06/30/2026 1190308482